Ulcerative colitis  by Ordás, Ingrid et al.
Seminar
1606 www.thelancet.com   Vol 380   November 3, 2012
Lancet 2012; 380: 1606–19
Published Online
August 20, 2012
http://dx.doi.org/10.1016/
S0140-6736(12)60150-0
Division of Gastroenterology 
(I Ordás MD, 
Prof L Eckmann  MD, 
Prof W J Sandborn MD), 
Department of Surgery 
(Prof M Talamini MD), 
University of California, 
San Diego, CA, USA; Division of 
Gastroenterology, Hospital 
Clinic, Centro de Investigación 
Biomédica en Red en el Área 
temática de Enfermedades 
Hepáticas y Digestivas, Institut 
d’Investigacions Biomèdiques 
August Pi i Sunyer (IDIBAPS), 
University of Barcelona, 
Barcelona, Spain (I Ordás); and 
Department of Medicine, 
Division of Gastroenterology 
and Hepatology, Charité 
Medical Centre, Virchow 
Hospital, Medical School of the 
Humboldt–University of Berlin, 
Berlin, Germany 
(Prof D C Baugmart MD)
Correspondence to:
Dr William J Sandborn, Division 
of Gastroenterology, University 
of California San Diego, La Jolla, 
CA 92093-0956, USA
wsandborn@ucsd.edu
See Online for appendix
Ulcerative colitis
Ingrid Ordás, Lars Eckmann, Mark Talamini, Daniel C Baumgart, William J Sandborn
Ulcerative colitis is an idiopathic, chronic inﬂ ammatory disorder of the colonic mucosa, which starts in the rectum and 
generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with 
proctitis or left-sided colitis might have a caecal patch of inﬂ ammation. Bloody diarrhoea is the characteristic symptom of 
the disease. The clinical course is unpredictable, marked by alternating periods of exacerbation and remission. In this 
Seminar we discuss the epidemiology, pathophysiology, diagnostic approach, natural history, medical and surgical 
management, and main disease-related complications of ulcerative colitis, and brieﬂ y outline novel treatment options. 
Enhanced understanding of how the interaction between environmental factors, genetics, and the immune system 
results in mucosal inﬂ ammation has increased knowledge of disease pathophysiology. We provide practical therapeutic 
algorithms that are easily applicable in daily clinical practice, emphasising present controversies in treatment 
management and novel therapies.
Introduction
Ulcerative colitis and Crohn’s disease are the two main 
forms of inﬂ ammatory bowel disease. Despite some 
shared characteristics, these forms can be distinguished 
by diﬀ erences in genetic predisposition, risk factors, 
and clinical, endoscopic, and histological features. The 
precise cause of inﬂ ammatory bowel disease is un known; 
however, genetically susceptible individuals seem to have 
a dysregulated mucosal immune response to commensal 
gut ﬂ ora, which results in bowel inﬂ ammation.1
Inﬂ ammation in ulcerative colitis is characteristically 
restricted to the mucosal surface. The disorder starts in 
the rectum and generally extends proximally in a con-
tinuous manner through the entire colon; however, some 
patients with proctitis or left-sided colitis might have a 
caecal patch of inﬂ ammation. Disease distribu tion is 
stratiﬁ ed by the extent of colonic involvement, from 
proctitis to left-sided colitis or extensive colitis (pancolitis).2
Epidemiology
Geography, age, and sex
Ulcerative colitis is more prevalent than Crohn’s disease. 
North America and northern Europe have the highest 
incidence and prevalence rates of ulcerative colitis, 
with incidence varying from nine to 20 cases per 
100 000 person-years, and prevalence rates from 156 to 
291 cases per 100 000 people (table 1). Rates are lowest 
in the southern hemisphere and eastern countries 
(appendix pp 1–2). Incidence has increased in countries 
that have adopted an industrialised lifestyle, which 
suggests that environmental factors might be crucial in 
the triggering of disease onset.
Ulcerative colitis has a bimodal pattern of incidence, 
with the main onset peak between ages 15 and 30 years,12 
and a second smaller peak between ages 50 and 70 years. 
Studies have noted either no preference regarding sex,13 
or a slight predilection for men.12
Genetic factors
A family history of inﬂ ammatory bowel disease is the most 
important independent risk factor.14 The risk is particularly 
high in ﬁ rst-degree relatives: 5·7–15·5% of patients with 
ulcerative colitis have a ﬁ rst-degree relative with the same 
disease.15,16 Furthermore, Ashkenazi Jews have a rate of 
ulcerative colitis that is three to ﬁ ve times higher than that 
of other ethnic groups, which suggests another genetic 
link. However, these diﬀ erences are lessening, which 
supports the importance of environ mental factors in the 
cause of the disease.17 Finally, monozygotic twins have 
concordance rates for ulcerative colitis of 6–13%.18,19
Environmental factors
Incidence of ulcerative colitis is higher in developed 
countries than in developing countries, and in urban 
versus rural areas. These ﬁ ndings could be partly 
explained by increased access to health care and better 
medical records in more developed than less developed 
countries. Furthermore, improved sanitation in indus-
trialised countries might reduce exposure to enteric 
infections during childhood, thus restricting maturation 
of the mucosal immune system, which could result in an 
inappropriate immune response when exposure to 
infectious microorganisms occurs later in life.13,20
Several environmental factors act as triggers or 
protective factors for ulcerative colitis, with cigarette 
smoking being the most consistent. A meta-analysis21 
showed that smoking is protective against ulcerative 
colitis compared with non-smoking (odds ratio [OR] 
0·58, 95% CI 0·45–0·75). Patients with ulcerative colitis 
Search strategy and selection criteria
We searched PubMed, Cochrane, and Ovid between 2000 and 
2012 with medical subject heading terms “ulcerative colitis” 
and “inﬂ ammatory bowel diseases”, combined with the 
subheadings “diagnosis”, “epidemiology”, “etiology”, 
“pathophysiology”, “genetics”, “therapy”, “surgery”, and 
“complications”. We critically reviewed all relevant articles 
published in English. For treatment and prevention 
strategies, we regarded randomised placebo-controlled trials 
and meta-analyses as the most important study types. We 
reviewed relevant abstracts presented at major 
gastrointestinal meetings.
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who smoke tend to have a more mild disease course than 
do non-smokers, and disease activity is often increased in 
those who stop smoking.22
Episodes of previous gastrointestinal infection (eg, 
Salmonella spp, Shigella spp, and Campylobacter spp) 
double the risk of subsequent development of ulcerative 
colitis, which suggests that acute intestinal infection 
might lead to changes in gut ﬂ ora, hence triggering the 
start of a chronic inﬂ ammatory process in genetically 
predisposed individuals.23,24 Weak epidemiological evi-
dence exists for an association between exposure to non-
selective non-steroidal anti-inﬂ ammatory drugs and 
onset or relapse of ulcerative colitis.25 Appendicectomy 
is protective against ulcerative colitis, with the eﬀ ect 
mainly limited to patients with acute appendicitis before 
age 20 years.26 A meta-analysis27 showed that appendi-
cectomy reduced the risk of development of ulcerative 
colitis by 69% (OR 0·31, 95% CI 0·25–0·38). Appendi-
cectomy has been used to treat ulcerative colitis.28Although 
several retrospective studies29,30 have postulated a seasonal 
variation in the occurrence of ulcerative colitis ﬂ ares, this 
association is fairly weak.
No data support psychological stress as a trigger for 
onset or relapse of ulcerative colitis.31 Use of oral 
contraceptives is moderately associated with disease 
onset.32 Breastfeeding is protective against subsequent 
development of ulcerative colitis (0·56, 0·38–0·81), but 
only when the duration of breastfeeding is more than 
3 months.33
Pathophysiology
Epithelial barrier
Figure 1 shows the pathophysiology of ulcerative colitis. 
The epithelial barrier, covered by a mucinous layer, is 
the ﬁ rst-line defence of the mucosal immune system, 
because it provides physical separation between host 
immune cells and luminal microbes, and synthesises 
antimicrobial peptides. In ulcerative colitis, synthesis 
and alteration of sulphation of some colonic mucin 
subtypes (mucin 2) is decreased.34 Damage to the 
epithelial barrier leads to increased permeability, possibly 
due to defective regulation of tight junctions.35 This 
barrier loss enables increased uptake of luminal antigens; 
however, whether such dysfunction precedes ulcerative 
colitis or results from chronic inﬂ ammation is unclear.
In addition to creation of a physical barrier, the 
intestinal epithelium contributes to host defence by 
producing antimicrobial peptides (eg, defensins), thus 
limiting bacterial invasion. Expression of selected human 
beta-defensins is upregulated in colonic samples of 
patients with ulcerative colitis. It is unclear whether this 
increase in defensin production is induced in response 
to microorganisms, inﬂ ammatory cytokines, or both.36,37
Commensal microﬂ ora
Normally, the intestinal immune system maintains 
equilibrium between tolerance to commensal ﬂ ora and 
dietary antigens, and adequate responsiveness to enteric 
pathogens. Evidence from genetically engineered 
animal models, which develop chronic intestinal in-
ﬂ ammation after colonisation with commensal gut 
bacteria, but remain disease free in bacteria-free 
conditions, suggests a primary role of non-pathogenic 
enteric bacteria in the pathogenesis of ulcerative 
colitis.38,39 Studies in human beings likewise support the 
importance of enteric microﬂ ora, not only in the 
pathogenesis of the disease, but also potentially in the 
severity of intestinal inﬂ ammation40 and disease 
phenotype (ulcerative colitis vs Crohn‘s disease).41 
Therefore, ulcerative colitis seems to result from a 
breakdown of the homoeostatic balance between the 
host’s mucosal immunity and the enteric microﬂ ora, 
which results in an aberrant immune response against 
commensal non-pathogenic bacteria.
Antigen recognition
Antigens activate the innate immune response 
through interaction with macrophages and dendritic 
cells. Dendritic cells can send dendrites outside the 
epithelium, interdigitated in the intestinal epithelial 
cells, to sample bacteria and other antigens in the 
lumen.42 The lamina propria is populated by macro-
phages and dendritic cells that present antigens to B cells 
and T cells, which leads to activation of adaptive immune 
responses. In patients with ulcerative colitis, numbers of 
activated and mature dendritic cells are increased with 
increased stimulatory capacity, and their circulating 
numbers correlate with disease activity, which suggests 
an important role of these cells in the start and 
perpetuation of inﬂ ammation.43
Dendritic cells express a broad range of microbial 
pattern-recognition receptors, including Toll-like recep-
tors (TLR) and NOD-like receptors. The main role of TLR 
signaling is to provide defence against pathogens and 
protection from epithelial injury, thereby contrib uting to 
intestinal homoeostasis and maintenance of the epithelial 
barrier. Normal intestinal epithelial cells express mainly 
Country Study period Incidence* Prevalence†
North America
Herrinton LJ, et al3 USA (California) 1996–2002 12·0 155·8
Loftus CG, et al4 USA (Olmsted County, MN) 1990–2000 8·8 214
Kappelman MD, et al5 US (33 states) 2003–04 ·· 238
Bernstein CN, et al6 Canada 1998–2000 9·9-19·5 162–249
Europe
Manninen P, et al7 Finland 1986–2000 19·6 291
Vind I, et al8 Denmark 2003–05 13·4 ··
Bjornsson S, et al9 Iceland 1990–94 16·5 ··
Stewenius J, et al10 Sweden 1958–82 9·4 ··
Rubin GP, et al11 England ·· 13·9 243·4
*Cases per 100 000 person-years. †Cases per 100 000 people.
Table 1: Incidence and prevalence rates of ulcerative colitis from selected countries
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TLR3 and TLR5, whereas TLR2 and TLR4 are scarce or 
absent.44 By contrast, TLR4 expression is substantially 
increased in lamina propria cells of patients with 
ulcerative colitis.45 Polymorphisms in TLRs can alter 
susceptibility to enteric infections or change the ability of 
the adaptive immune response to become tolerant to 
commensal bacteria. The TLR4 D299G polymorphism 
might be an important risk factor for ulcerative colitis in 
white patients.46 Activation of TLRs triggers innate and 
adaptive immune responses that lead to activation of the 
transcription factor nuclear factor-κB (NF-κB) and other 
transcription factors that are important in activation of 
the inﬂ ammatory cascade.47 In chronic intestinal inﬂ am-
mation, NF-kB regulates pro inﬂ ammatory and cell 
survival functions in macrophages and T cells,48,49 but is 
also protective in epithelial cells,50 which makes its role in 
intestinal inﬂ ammation complicated and dependent on 
cell type.
Dysregulation of immunological responses
In the mucosa of patients with ulcerative colitis, the 
homoeostatic balance between regulatory and eﬀ ector 
T-cells (eg, T-helper [Th] 1, Th2, and Th17) is disturbed. 
Evidence suggests that ulcerative colitis is associated 
with an atypical Th2 response mediated by non-classic 
natural killer T-cells producing interleukins 5 and 13. 
Interleukin 13 is of particular importance because it 
exerts cytotoxic functions against epithelial cells, in-
cluding induction of apoptosis and alteration of the 
protein composition of tight-junctions.35,51
Natural killer T-cells are increased in the lamina propria 
of an inﬂ amed colon and are capable of pro ducing many 
Th2 cytokines; ﬁ rst interleukin 4, which is then rapidly 
superseded by interleukin 13.52,53 Interleukin 13 can exert 
a positive feedback eﬀ ect on natural killer T-cells, thus 
amplifying tissue injury. Interleukin 13 and natural killer 
T-cells seem to have a key role in the pathogenesis of 
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Figure 1: Pathophysiology of ulcerative colitis
Disruption of tight junctions and the mucus ﬁ lm covering the epithelial layer causes increased permeability of the intestinal epithelium, resulting in increased uptake of 
luminal antigens. Macrophages and dendritic cells (innate immune cells), on recognition of non-pathogenic bacteria (commensal microbiota) through molecular pattern-
recognition receptors (TLR), change their functional status from tolerogenic to an activated phenotype. Activation of NF-kB pathways stimulates the transcription of 
proinﬂ ammatory genes, resulting in increased production of proinﬂ ammatory cytokines (TNF-α, interleukins 12, 23, 6, and 1β). After processing of antigens, macrophages 
and dendritic cells present them to naive CD4 T-cells, promoting diﬀ erentiation into Th2 eﬀ ector cells, characterised by production of interleukin 4. Natural-killer T cells are 
the main source of interleukin 13, which has been associated with disruption of the epithelial cell barrier. Circulating T cells bearing integrin-α4β7 bind to colonic 
endothelial cells of the microvasculature through the mucosal vascular addressin-cell adhesion molecule 1, whose expression is enhanced in the inﬂ amed intestine, leading 
to increased entry of gut-speciﬁ c T cells into the lamina propria. Upregulation of inﬂ ammatory chemokines, such CXCL1, CXCL3, and CXCL8, leads to recruitment of 
circulating leucocytes which perpetuates the cycle of inﬂ ammation. TLR=Toll-like receptor. HLA=human leucocyte antigen. IL=interleukin. TNF=tumour necrosis factor. 
NF- κB=nuclear factor-κB. Th=T-helper. NKT=natural killer T-cell. CXCL=chemokine. Treg=regulatory T cell. MAdCAM-1=mucosal addressin-cell adhesion molecule 1.
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ulcerative colitis, because evidence54 shows that blockade 
of this interleukin and depletion of these T cells can 
prevent colitis development. Loss-of-function mutations 
in either interleukin-10 receptor-1 or intereukin-10 
receptor is associated with severe ulcerative colitis, 
probably because of an absence of interleukin-10 
signalling.55
Tumor necrosis factor (TNF)-α is elevated in the blood,56 
stool samples57 and mucosa58 of patients with ulcerative 
colitis. These ﬁ ndings, together with the eﬀ ectiveness of 
anti-TNF treatment for ulcerative colitis, corroborate the 
importance of TNF-α in the pathogenesis of the disease.
Leucocyte recruitment
Recruitment of circulating leucocytes from the systemic 
circulation to the inﬂ amed mucosa by release of 
chemoattractants, such as CXCL8 (which is upregulated 
in patients with ulcerative colitis),59 is important for 
ampliﬁ cation of the inﬂ ammatory response.
Proinﬂ ammatory cytokines upregulate the expres-
sion of adhesion molecules—eg, mucosal addressin 
cellular adhesion molecule-1 (MadCAM-1)60—on the 
vascular endothelium of mucosal blood vessels, which 
promotes leucocyte adhesion and extravasation into the 
tissue, thus perpetuating the cycle of inﬂ ammation. 
MAdCAM-1, through interaction with α4β7 integrin, 
mediates lympho cyte homing to gut-associated lymphoid 
tissue during inﬂ ammation.61 Antibodies to either 
MAdCAM-1 or its ligand α4β7 (eg, vedolizumab) and to 
the β7 subunit of this heterodimeric integrin (eg, 
etrolizumab) prevent lymphocyte recruit ment and reduce 
the severity of colonic inﬂ ammation (appendix p 6).
Genetic factors
Genome-wide association studies have revolutionised 
the complex ﬁ eld of polygenic diseases and have led 
to the discovery of several susceptibility genes for 
ulcerative colitis, thus providing novel insights into 
disease pathogenesis. Associations within the major 
histo compatibility complex class-2 region near HLA-
DRA are the most signiﬁ cant.62 HLA haplotype 
DRB1*0103 is signiﬁ cantly associated with disease 
susceptibility, extensive disease, and an increased risk of 
colectomy (OR 84, 95% CI 9–785; p<0·0001).63 Up to now, 
47 susceptibility loci have been associated with ulcerative 
colitis, including 20 that overlap with Crohn’s disease—
eg, interleukins 23 and 10, and janus kinase-2 pathway 
genes (appendix pp 3–5).64 Identiﬁ cation of risk loci 
speciﬁ c for ulcerative colitis, such as hepatocyte nuclear 
factor-4α, CDH1, and laminin-β1, which code for proteins 
that play key parts in epithelial cell adhesion, emphasises 
the role of defective barrier function in disease patho-
genesis.65 Mutation in the protein E-cadherin is the ﬁ rst 
documented genetic correlation between colorectal 
cancer and ulcerative colitis.66
In summary, the main abnormality driving inﬂ am-
mation in ulcerative colitis involves an exaggerated T-cell 
(modiﬁ ed atypical Th2) response, which causes mucosal 
hyper-responsiveness to commensal bacteria in genet-
ically predisposed hosts. Evolving knowledge of disease 
pathophysiology is crucial for development of novel 
treatment strategies (appendix p 6).
Diagnosis
Diagnosis of ulcerative colitis is based on clinical symp-
toms conﬁ rmed by objective ﬁ ndings from endo scopic67 
and histological examinations (panel 1, ﬁ gure 2). Infec-
tious (eg, bacterial, parasitic, viral, and fungal ) and non-
infectious (eg, microscopic colitis, malabsorption of 
bile acid, bacterial overgrowth, malignant causes, and 
diarrhoea induced by drugs) causes of diarrhoea should 
be ruled out before a diagnosis is made. Inﬂ ammation 
generally starts in the rectum and extends proximally, in 
an uninterrupted pattern, involving part of, or the entire, 
colon. However, some patients with proctitis or left-sided 
colitis have a cecal patch of inﬂ ammation,68 and rectal 
sparing is sometimes observed. Dependent on the 
colonic segments involved, disease extent can be 
classiﬁ ed as proctitis, left-sided colitis, or pancolitis.2 
Extent should be assessed at diagnosis, because know-
ledge of the anatomic extent of mucosal inﬂ ammation is 
essential for selection of appropriate topically admin-
istered treatments, and has prognostic implications for 
short-term and long-term follow-up. Classiﬁ cation of 
Panel 1: Diagnosis of ulcerative colitis
Clinical features
• Rectal bleeding
• Diarrhoea
• Urgency
• Tenesmus
• Abdominal pain
• Fever (severe cases)
• Extraintestinal manifestations
Endoscopic features
• Loss of vascular pattern
• Erythema 
• Granularity
• Friability
• Erosions
• Ulcerations
• Spontaneous bleeding
Pathological features
• Distortion of crypt architecture
• Crypt abscesses
• Lamina propria cellular inﬁ ltrate (plasma cells, 
eosinophils, lymphocytes)
• Shortening of the crypts
• Mucin depletion
• Lymphoid aggregates
• Erosion or ulceration
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disease severity is based on the number of daily stools 
and the presence (or absence) of systemic signs of 
inﬂ am mation, such as fever and tachycardia (panel 2).2 
Patients with pancolitis might sometimes show diﬀ use 
inﬂ ammation in the distal few cm of the terminal ileum. 
This symptom, known as backwash ileitis, and rectal 
sparing, are both highly associated with the presence of 
concomitant primary sclerosing cholangitis.69 The appen-
dix (p 7) shows other extraintestinal manifestations.
Natural history of the disease
The clinical course of ulcerative colitis is characterised by 
alternating periods of remission and relapse. At 
diagnosis, most patients have mild to moderate 
symptoms, and less than 10% have severe disease.70 On 
the basis of the pattern of disease activity in time, patients 
can be classiﬁ ed into diﬀ erent subgroups. In a 
population-based study, 580 (50%) of 1161 the patients 
remained in clinical remission or with mild symptoms 
after 10 years of follow-up; in almost 661 (57%) of 
patients, the disease followed a chronic intermittent 
course; and 209 (18%) had chronic continuous activity.71 
A short period (2 years) from diagnosis to the ﬁ rst ﬂ are, 
presence of fever or weight loss at diagnosis, and active 
disease in the preceding year might increase the risk of 
subsequent relapse.72
Extension of colonic disease can occur in time. At 
diagnosis, 30–50% of patients have disease conﬁ ned to 
the rectum or the sigmoid colon (distal colitis), 20–30% 
have left-sided colitis, and about 20% have pancolitis.73 
Of those with distal colitis, 25–50% progress to more 
extensive forms of the disease in time.74 Patients who are 
diagnosed at a young age (eg, 15–30 years), and those 
with concomitant primary sclerosing cholangitis, are 
more likely to have extensive disease at presentation 
than are those diagnosed later in life. Disease ﬂ ares 
associated with progression of anatomic extent (eg, from 
proctitis to left-sided colitis or pancolitis) usually follow 
a severe course and require more intensive medical 
treat ment than do non-progressive ﬂ ares.75 The 
anatomical extent of mucosal inﬂ ammation is clearly 
one of the most important factors determining disease 
course; patients with more severe disease tend to have 
more extensive forms (pancolitis) than do those with 
less severe disease. Furthermore, disease extent is an 
important predictor of colectomy (patients with extensive 
colitis have a risk of 3·5 to four times greater than those 
with proctitis)71,76 and colorectal cancer.77 Colectomy rates 
within 10 years of diagnosis are 20–30%, increasing 
to 40% in patients with long-lasting and extensive 
disease.72,78 In time, rates of colectomy decrease, with 
most done in the ﬁ rst 2 years of disease onset and in 
patients with pancolitis.79
Despite the often severe disease manifestations, 
patients with ulcerative colitis do not have an increased 
mortality risk compared with the general population.80
Management
Medical treatment
Treatment goals in ulcerative colitis have evolved 
from treatment of symptoms and induction of clinical 
remission to more stringent outcomes, including 
maintenance of steroid-free remission, prevention of 
hospital admission and surgery, mucosal healing, 
improved quality of life, and avoidance of disability.81 
Treatment for ulcerative colitis consists mainly of 
mesalazine, corticosteroids, immunosup pressive drugs, 
and monoclonal antibodies to TNF-α. Treatment success 
is dependent on several factors, such as use of the right 
drug for the right indication (induction vs maintenance), 
optimisation of the dose, and maximisa tion of drug 
adherence (non-adherence to mesalazine is associated 
with increased rates of relapse).82
Treatment should be tailored to disease activity (mild, 
moderate, severe) and the extent of colonic involvement 
(proctitis, left-sided colitis, or pancolitis; ﬁ gure 3).83–85
Figure 2: Mayo endoscopic score for ulcerative colitis
(A) Score 0=normal; endoscopic remission. (B) Score 1=mild; erythema, 
decreased vascular pattern, mild friability. (C) Score 2=moderate; marked 
erythema, absent vascular pattern, friability, erosions. (D) Score 3=severe; 
spontaneous bleeding, ulceration. Images courtesy of Elena Ricart.
A B
C D
Panel 2: Montreal classiﬁ cation of extent and severity of ulcerative colitis
• E1 (proctitis): inﬂ ammation limited to the rectum
• E2 (left-sided; distal): inﬂ ammation limited to the splenic ﬂ exure
• E3 (pancolitis): inﬂ ammation extends to the proximal splenic ﬂ exure
• S0 (remission): no symptoms
• S1 (mild): four or less stools per day (with or without blood), absence of systemic 
symptoms, normal inﬂ ammatory markers
• S2 (moderate): four stools per day, minimum signs of systemic symptoms
• S3 (severe): six or more bloods per day, pulse rate of ≥90 beats per min, temperature 
≥37·5°C, haemoglobin concentration <105 g/L, erythrocyte sedimentation rate 
≥30 mm/h
E=extent. S=severity.
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Induction of response and remission
Mild to moderately active disease
Mesalazine is the ﬁ rst-line treatment for mild to moderately 
active ulcerative colitis.83–86 Oral mesalazine is available in 
diﬀ erent formulations (table 2) with diﬀ erent release 
characteristics (ﬁ gure 4), all of which have similar 
eﬀ ectiveness.83,84,87 Mild to moderate proctitis is best treated 
with 1 g per day of topical mesalazine (suppositories), 
which is more eﬀ ective than either topical steroids88 or oral 
mesalazine. Mildly to moderately active proctosigmoiditis 
can be treated with topical or oral mesalazine, whereas 
extensive colitis should always receive oral mesalazine. 
Combined treatment (oral and topical) leads to higher 
remission rates than does either treatment alone.89,90
The optimum dose of oral mesalazine for induction of 
remission in mild disease is 2·4 g per day. Patients with 
moderate symptoms, those with previous steroid use, and 
those with a history of several drugs are more likely to 
beneﬁ t from higher doses (4·8 g per day) than are other 
patients.91,92 Oral mesalazine generally acts in 2–4 weeks.87 
Probiotics are not eﬀ ective.93 If symptoms do not improve 
quickly, oral corticosteroids should be started.84 Although 
almost 70% of patients respond to the ﬁ rst course of 
corticosteroids, 22% develop steroid dependency in the 
ﬁ rst year of treatment, and only half maintain 
corticosteroid-free remission.94 For initial corticosteroid 
dosage, diﬀ erences between prednisone 40 mg per day and 
60 mg per day were not signiﬁ cant, and the 60 mg dose 
had increased toxic eﬀ ects.95 No randomised trials have 
assessed the optimum duration of corticosteroid treatment 
and a tapering protocol to maximise its eﬀ ectiveness, but 
maximum dose should be maintained until a signiﬁ cant 
clinical improvement is achieved. Patients with cortico-
steroid-dependent disease, and those who relapse despite 
optimum doses of mesalazine, can be treated with 
azathioprine or mercaptopurine,96 but the eﬀ ectiveness of 
these drugs is fairly moderate.97 The dose of azathioprine is 
2·5 mg/kg daily and for mercaptopurine is 1–1·5 mg/kg. 
Outpatients with moderately active ulcerative colitis who 
do not respond to conventional treatment can be given 
inﬂ iximab or adalimumab,98–100 either alone or in 
combination with azathioprine.
A comparative eﬀ ectiveness trial showed that anti-
TNF treatment with inﬂ iximab in combination with 
Mild Moderate Severe
Extensive Oral mesalazine 
2·4–4·8 g/d±topical  
Distal or left-sided
Oral mesalazine
2·4–4·8 g/d±topical
Topical mesalazine
1–4 g/d
Response?
Yes
Yes
No
Response?
Yes
No
Response?
Evaluate after
3–5 days
Yes
No
Response?
Yes
No
or steroid 
dependency
Response?
NoMesalazine 
maintenance
oral±topical 
Mesalazine 
maintenance
oral±topical 
Oral corticosteroids
40–60 mg/d
Taper steroids
Azathioprine 2·5 mg/kg
and/or *Inﬂiximab 5 mg/kg
(0, 2, 6 weeks) or
*Adalimumab 160–80 mg 
subcutaneous
A B
Admit patient to hospital to receive
intravenous corticosteroids
Fluid and electrolyte replacement
Subcutaneous heparin
Nutritional support
Avoid anticholinergic 
or narcotic drugs
Stool cultures
Sigmoidoscopy with biopsies 
(exclude cytomegalovirus)
Additional
measures
Taper steroids
Inﬂiximab 5 mg/kg
(0–2–6 weeks)
Assess after ﬁrst dose
Ciclosporin
2 mg/kg intravenously
5–10 mg/kg orally
[200–400 ng/mL]/48–72 h
Surgery
Surgery Response?
Yes
No
Inﬂiximab
†
†
Azathioprine 2·5 mg/kg
±mesalazine
Inﬂiximab 5 mg/kg/8 weeks
±azathioprine 2·5 mg/kg
Figure 3: Treatment algorithm for ulcerative colitis of varying severities
(A) Mild to moderate ulcerative colitis. (B) Severe ulcerative colitis. †Carefully selected patients at specialist centres.*Dependent on the severity of symptoms and how 
quickly remission needs to be induced.
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azathioprine was more eﬀ ective than either drug alone.101 
Combination treatment is the preferred strategy for most 
patients. In the UK, inﬂ iximab is not recommended in the 
outpatient setting because of a scarcity of data for cost-
eﬀ ectiveness.83 Inﬂ iximab is given intravenously at 
5 mg/kg at 0, 2, and 6 weeks, and every 8 weeks thereafter. 
Adalimumab is given subcutaneously at 160 mg at week 0, 
80 mg at week 2, and then 40 mg every 2 weeks. The 
appendix (pp 8–9) shows contraindications and pre ventive 
measures before anti-TNF treatment.
Severe active disease
Patients with severe colitis should be admitted to hospital 
for treatment with intravenous corticosteroids (ﬁ gure 3), 
because of their high risk for colectomy.102 Concomitant 
infection with Clostridium diﬃ  cile and cytomegalovirus 
should be ruled out.103,104 The overall response rate to 
intravenous corticosteroids in severe acute colitis is almost 
70%. After the ﬁ rst course of corticosteroids, rates of 
colectomy in the short term (from the same admission up 
to 2 months) are about 30%.105 Early identiﬁ cation of 
patients for whom intravenous cortico steroids are likely to 
be ineﬀ ective, careful monitoring by gastroenterologists 
and surgeons, and early introduction of rescue treatments 
for patients with steroid-refractory disease are crucial to 
minimise morbidity and mortality. The likelihood of 
colectomy is related to disease severity106 and presence of 
deep colonic ulcerations on admission.107 Continued high 
numbers of daily stools, presence of fecal blood, and 
elevated concentrations of C-reactive protein after 3 days of 
intensive treatment with corticosteroids are the main 
factors associated with steroid refractoriness, with an 
Manufacturer Unit strength Formulation Sites of delivery Daily dose
Induction of 
remission
Maintenance of 
remission
Olsalazine
Dipentum UCB Manufacturing, Rochester, 
NY, USA
250 mg tablets 5-ASA dimer linked by azo-bond Colon 2–3 g* 1 g*
Sulfasalazine
Azulﬁ dine† Pﬁ zer, NY, USA 500 mg tablets (containing 
200 mg 5-ASA)
5-ASA linked to sulfapyridine by azo-bond Colon 4–6 g* 
(0·8–1·6 g 5-ASA)
4–6 g* 
(0·8–1·6 g 5-ASA)
Salazopyrin‡ Pﬁ zer, Europe 500 mg tablets (containing 
200 mg 5-ASA)
5-ASA linked to sulfapyridine by azo-bond Colon 4–6 g* 
(0·8–1·6 g 5-ASA)
4–6 g* 
(0·8–1·6 g 5-ASA)
Balsalazide
Colazal† Saliz Pharmaceuticalos, 
Raleigh, NC, USA
750 mg tablets (containing 
267 mg 5-ASA)
5-ASA linked to 4-aminobenzoyl-beta-alanine by 
azo bond
Colon 2–6·75 g* 
(0·7–2·4 g 5-ASA)
2–6·75 g* 
(0·7–2·4 g 5-ASA)
Colazide§ Almirall, London, UK 750 mg tablets (containing 
267 mg 5-ASA)
5-ASA linked to 4-aminobenzoyl-beta-alanine by 
azo bond
Colon 2–6·75 g* 
(0·7–2·4 g 5-ASA)
2–6·75 g* 
(0·7–2·4 g 5-ASA)
Mesalazine
Asacol† Warner Chilcott Laboratories, 
Rockaway, NJ, USA
400 mg tablets 5-ASA coated with Eudragit-S Distal ileum, 
colon
2·4–4·8 g¶ 1·6 g–2·4 g¶
Asacol HD† Warner Chilcott Laboratories, 
Rockaway, NJ, USA
800 mg tablets 5-ASA coated with Eudragit-S Distal ileum, 
colon
2·4–4·8 g¶ 1·6 g–2·4 g¶
Claversal‡  Merck Sharp, Madrid, Spain 250–500 tablets 5-ASA coated with Eudragit-L Ileum, colon 1·5–4 g¶ 0·75–4 g¶
Salofalk‡ Dr Falk Pharma, Freiburg, 
Germany
0·5§, 1¶, 1·5¶ g sachets 5-ASA coated with Eudragit-L Ileum, colon 1·5–4 g¶ 0·75–4 g¶
Salofalk 
Granu-Stix†
Dr Falk Pharma, Freiburg, 
Germany
0·5 , 1 g sachets 5-ASA coated with Eudragit-L100, 
polyacrylate-dispersion, povidone K (Eudragit-NE 
40D, Nonoxinol 100), simeticone
Colon (80%), 
sigmoid and 
rectum
1·5–4·5 g¶ 1·5–3 g¶
Apriso† Salix pharmaceuticals, Raleigh, 
NC, USA
375 mg tablets 5-ASA coated with Eudragit-L100, 
polyacrylate-dispersion, povidone K (Eudragit-NE 
40D, Nonoxinol 100), simeticone
Colon (80%), 
sigmoid and 
rectum
1·5–4·5 g¶ 1·5–3 g¶
Pentasa‡ Ferring Pharmaceuticals, Kiel 
Germany
250–500 mg tablets, 1 g 
sachets
5-ASA microgranules coated in ethylcellulose Small bowel, 
colon
2–4 g¶ 1·5–4 g¶
Lialda† Shire US, Wayne, PA, USA 1200 mg tablets 5-ASA coated with Multi Matrix system with 
lipophilic and hydrophilic matrices
Ileum, colon 2·4–4·8 g¶ 2·4 g¶
Mezavant‡ Shire, Dublin, Ireland 1200 mg tablets 5-ASA coated with Multi Matrix system with 
lipophilic and hydrophilic matrices
Ileum, colon 2·4–4·8 g¶ 2·4 g‡ ¶
5-ASA=5-aminosalicylic acid. *Divided doses. †USA. ‡Europe. §UK. ¶Single dose.
Table 2: Oral aminosalicylate formulations
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immediate risk of col ectomy up to 85%.108 No improvement 
after 3–5 days of intravenous steroids is an indication to 
start im mediate rescue treatment.83,84 Inﬂ iximab, 
ciclosporine, tacrolimus, and surgery are all eﬀ ective 
rescue treatments (ﬁ gure 3).
Treatment strategies should be individualised for 
each patient, accounting for age, comorbidities, and 
maintenance treatment at the time of relapse (patients 
starting ciclosporine after azathioprine failure are more 
likely to need colectomy than are those who have not 
received azathioprine).109 Ciclosporine and tacrolimus are 
highly eﬀ ective for short-term clinical improvement with 
response rates of about 60–80%.110,111 However, use of 
these drugs has been limited by serious adverse events112 
and low eﬀ ectiveness for maintenance of colectomy-free 
remission in the long term.109,111 Ciclo sporine is ﬁ rst given 
intravenously at doses of 2–4 mg/kg per day,110,113 and is 
then converted to an oral micro emulsion at doses of 
5–10 mg/kg. Doses are adjusted to maintain trough 
serum concentrations between 200 and 400 ng/mL. 
Tacrolimus is given orally at doses of 0·1–0·2 mg/kg. 
Doses are adjusted to maintain trough serum concen-
trations between 5 and 10 ng/mL. The appendix (p 10) 
lists adverse eﬀ ects of ciclosporine and tacrolimus. 
Patients given steroids and ciclosporine or tacrolimus 
should receive prophylaxis with cotrimoxazole against 
Pneumocystis jirovecii.114 Similar to ciclosporine, inﬂ iximab 
is likewise highly eﬀ ective, achieving clinical response 
rates of 70% (95% CI 65–71) and remission rates of 40% 
(36–44).115 Inﬂ iximab is ﬁ rst given intra venously at a dose 
of 5 mg/kg at weeks 0, 2, and 6.
Whether the optimum rescue treatment in patients with 
severe steroid-refractory colitis is ciclosporine (or 
alternatively tacrolimus) or inﬂ iximab is unclear. A 
randomised trial showed similar short-term response rates 
with both drugs (ciclosporine 85·4% vs inﬂ iximab 85·7%; 
p=0·97) and no diﬀ erence in colectomy rates after 
3 months (18% vs 21%; p=0·66).116 In view of these similar 
outcomes, inﬂ iximab might be preferred compared with 
ciclosporine because it can be continued as maintenance 
treatment in responding patients, particularly in those for 
whom azathioprine has been ineﬀ ective. Switching of 
cyclosporine to inﬂ iximab or vice versa could be eﬀ ective 
rescue treatment for carefully selected patients at specialist 
centres.117 Never theless, this strategy has a substantial risk 
of serious adverse events with restricted eﬀ ectiveness in 
the long term.118
Maintenance of remission
Mesalazine is the basis of treatment for maintenance of 
remission in ulcerative colitis. However, the most 
appropriate maintenance treatment for an individual 
patient is established by several factors, including disease 
extent and severity, treatment for induction of remission, 
and failure of previous maintenance treat ments. Most 
patients can stay in remission using oral once-daily 
mesalazine at doses of 1·6–3·0 g per day, maintaining 
remission rates of about 70–90%.119,120 No signiﬁ cant dose–
response relation has been noted between diﬀ erent 
doses.121 Remission of proctitis and distal colitis can be 
maintained with rectal mesalazine; probiotics are not 
eﬀ ective.93 Corticosteroids, either topical or oral, are not 
eﬀ ective for maintenance of remission. Patients who have 
frequent relapses despite optimum doses of mesalazine, 
those with steroid dependency, and those previously 
treated with cyclo sporine or tacrolimus for a severe ﬂ are, 
should be given azathioprine122 or antiTNF drugs for 
maintenance of remission.96,98,99,123 Azathioprine dis-
continuation is associated with a high rate of relapse.124
Patients with steroid-refractory ulcerative colitis 
who have responded to induction with inﬂ iximab or 
adalimumab should be maintained on this treatment,125 
because scheduled retreatment (every 8 weeks for inﬂ ixi-
mab and every 2 weeks for adalimumab) is eﬀ ective for 
maintenance of remission and mucosal healing,98,99 and for 
reduction of hospital admission and colectomy rates.126 In 
the UK, inﬂ iximab and adalimumab are not recom mended 
for maintenance treatment because of low rates of steroid-
free remission.83 Mucosal healing at week 8 is associated 
with a reduced rate of colectomy in the next year, and some 
clinicians have already incorporated endoscopic 
assessment at week 8 into clinical practice.127
Surgery for ulcerative colitis
Treatment
Although the basis of ulcerative colitis treatment is 
medical, about 20–30% of patients eventually need sur-
gery.78,128 Indications for surgical treatment of ulcerative 
colitis are divided into emergency, urgent, and elective. 
Emergency procedures are done for life-threatening 
complications of fulminant colitis that is unresponsive 
to medical treatment. Urgent surgery is indicated in 
Proctitis
Left-sided colitis
Pancolitis
Orally given
local release
of mesalazine
Enemas
(reach the 
splenic ﬂexure)
Foams
(reach the sigmoid colon)
Suppositories
(rectum, 15 cm beyond
the anal verge)
Topical treatment (±oral)
Oral treatment (±topical)
Figure 4: Release of mesalazine preparations 
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patients with severe ulcerative colitis admitted to hospital 
who do not respond to intensive medical treatment. 
Refractoriness or intolerance to long-term maintenance 
treatments and dysplasia or colorectal cancer are the main 
indications for elective procedures.129 Although mortality 
related to severe attacks of ulcerative colitis has substantially 
decreased to less than 1% in past decades,105 a delay in 
indicated surgery can increase the risk of postoperative 
complications and mortality.130
Choice of surgical procedure is dependent on 
several factors, including indication (urgent or elective), 
patient comorbidities, and surgeon expertise. The aim of 
emergency and urgent surgery is to restore patient health 
by removal of the burden of the inﬂ amed colon. Hence, 
the main procedure in these situations is a subtotal 
colectomy with a temporary ileostomy with no removal of 
the rectal stump.129 Construction of the pouch should be 
avoided in the acute setting because of a high risk of 
pelvic bleeding, sepsis, and injury to pelvic nerves. After 
the patient has fully recovered, a restorative operation 
with construction of the ileal-pouch anal anastomosis 
(IPAA) and ileostomy closure can be done with a reduced 
risk of complications.
Proctocolectomy with IPAA is the standard of care for 
elective surgery (ﬁ gure 5). Although colectomy with IPAA 
can be done at the time of pouch construction without a 
diverting ileostomy (one stage), the two-stage procedure is 
almost always preferred to minimise the risk of 
pelvic sepsis.131 With the advent of new tech nologies, 
laparoscopic proctocolectomy is evolving and becoming 
the procedure of choice in centres with much experience 
of this technique. Laparoscopic colectomy facilitates 
subsequent proctectomy and reservoir con struction,132 and 
is associated with a reduction in time to diverting ileostomy 
closure after creation of the IPAA.133 Although 
proctocolectomy with IPAA construction is the standard of 
care for surgical treatment, total colectomy with ileorectal 
anastomosis could be considered for carefully selected 
patients—eg, elderly people; however, in these cases, 
continued surveillance of the rectum is needed because of 
the persistent cancer risk.
Complications
Proctocolectomy is associated with substantial short-term 
and long-term morbidity. Early postoperative small-bowel 
obstruction occurs in up to 15% of patients after IPAA.134 
Pelvic sepsis is the most serious early complication of ileal 
pouch surgery, with rates up to 20%,135 and is the main 
cause of pouch failure. Early treatment is essential to 
minimise the negative eﬀ ect on the long-term pouch 
outcomes. Preoperative use of corticosteroids136 and 
inﬂ iximab,137 but not azathioprine,138 increases the risk of 
postoperative septic complications in the short-term. Long-
term complications include small bowel obstruction (30% 
at 10 years),134 anastomotic strictures (8–14% at 10 years),139 
pouchitis (50% by 3–4 years),140 sexual dysfunc tion, female 
infertility with a three times increased risk after IPAA,141 
and pouch failure.
Risk of colorectal cancer in ulcerative colitis is in creased 
in patients with long-standing disease compared with the 
general population, with a cumulative risk of 2% after 
10 years of diagnosis, 8% after 20 years, and 18% after 
A Proctocolectomy B Ileal J-pouch, stapled anastomosis,
temporary ileostomy
C Closure of the temporary ileostomy
Stapled ileal 
pouch-anal anastomosis
Ileal pouch-anal anastomosis
Ileal J-pouch
(reservoir)
Rectum removed
Entire colon removed
Figure 5: Proctocolectomy with ileal pouch-anal anastomosis
(A) Proctocolectomy. (B) Ileal J-pouch, stapled anastomosis, and temporary ileostomy. (C) Closure of the temporary ileopstomy. The entire surgical procedure is based 
on four steps: removal of the colon; pelvic dissection and rectum removal sparing the pelvic nerves and the anal sphincter; construction of the ileal pouch, usually with 
the last 30–40 cm of the terminal ileum; and anastomosis of the pouch to the canal anal. Ileal pouch-anal anastomosis can be done either with the double-stapled 
technique (as shown), or with mucosectomy and hand-sewn anastomosis; the stapled anastomosis is associated with better functional outcomes than the hand-sewn 
technique. The main drawback of the stapled technique is the risk of future episodes of inﬂ ammation in the remaining 1·5–2 cm of the rectal mucosa (cuﬃ  tis), which 
usually responds well to topical treatment.
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30 years.142 Colorectal cancer in patients with ulcerative 
colitis arises from unifocal or multifocal dysplastic mucosa 
in areas of chronic inﬂ ammation. Thus, for surveillance 
purposes, disease extent should be deﬁ ned as the most 
extensive disease at any time assessed histologically, rather 
than by endoscopic appearance.143 Guidelines recommend 
that all patients must undergo a screening colonoscopy, 
with several biopsies throughout the entire colon, after 
8 years of disease onset to assess the true microscopic 
extent of the disease.144–146
Several factors have been associated with an increased 
risk of colorectal cancer in patients with ulcerative colitis, 
with disease duration and extensive disease ﬁ rmly 
established as the two most important. Pancolitis has a 
risk that, compared with the general population, is 
14·8 times (95% CI 11·4–18·9) greater than that of 
colorectal cancer; left-sided colitis has an intermediate risk, 
and proctitis and proctosigmoiditis have little or no 
increased risk.147 Other factors that raise the risk of 
colorectal cancer include endoscopic and histological 
severity of inﬂ ammation,148 positive family history of 
sporadic colorectal cancer (two-times increased risk), 
strictures, shortened tubular colon, and several post-
inﬂ ammatory pseudopolyps (two-times increased risk). In 
patients with a concomitant diagnosis of primary 
sclerosing cholangitis, risk of colorectal cancer is up to 
four times greater than that in those with no primary 
sclerosing cholangitis. In patients with the disorder, 
endoscopic surveillance should start at the time of primary 
sclerosing cholangitis diagnosis and continue annually 
thereafter.149 Surveillance programmes should ideally be 
done in quiescent phases of the disease, because reactive 
atypia can be confounded with dysplasia in the presence of 
active inﬂ ammation.
Diagnosis of high-grade dysplasia in patients with 
ulcerative colitis is a strong recommendation for 
colectomy. By contrast, recommendations for ﬂ at low-
grade dysplasia are controversial (ﬁ gure 6). For the 
methodology of colonoscopic surveillance, four-quadrant 
non-targeted biopsy specimens, obtained from every 
10 cm of the colon and rectum, have been regarded as the 
standard of care.150 However, evidence now shows that 
chromoendoscopy yields signiﬁ cantly (7%, 95% CI 
3·2–11·3) more intraepithelial neoplastic lesions than do 
random biopsies, and this technique will probably become 
the standard of care.151
Despite many eﬀ orts to identify chemoprevention 
strategies that help reduce rates of colorectal cancer in 
patients with ulcerative colitis, little evidence is available. 
Results of one meta-analysis suggested that mesalazine , 
when taken on a long-term basis, can reduce the risk 
of colorectal cancer in patients with ulcerative colitis 
Figure 6: Surveillance of dysplasia in patients with ulcerative colitis144–46 
*Controversial.
All patients (irrespective of extent at diagnosis)
First screening colonoscopy
Several biopsies in each segment to assess true microscopic extent
Proctitis and proctosigmoiditis Left-sided colitis and pancolitis
Speciﬁc age guidelines for 
surveillance of colorectal cancer
First screening negative
Surveillance every 1–2 years
Adenoma-like
dysplasia-associated
lesion or mass
Non-adenoma-like
dysplasia-associated
lesion or mass
Annually from the time of 
primary sclerosing 
cholangitis diagnosis
High-grade dysplasia
Ulcerative colitis and primary
sclerosing cholangitis
Low-grade dysplasia
Close surveillance*
No dysplasia
elsewhere
Multifocal;
more than one occasion;
other risk factors for 
colorectal cancer
Colectomy
Within inﬂamed mucosa
8 years after disease onset
Flat dysplasia
elsewhere
No evidence of 
ﬂat dysplasia
elsewhere
Colectomy
Outside inﬂamed mucosa
Endoscope removal and
regular surveillance
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(OR 0·51, 95% CI 0·37–0·69).152 A large registry study 
showed that thiopurines were associated with a decrease of 
three times in the incidence of colorectal neoplasia in 
patients with extensive disease.153 Finally, a placebo-
controlled trial of ursodeoxycholic acid in patients with 
primary sclerosing cholangitis showed a protective eﬀ ect 
against colorectal dysplasia and cancer in patients with 
concomitant ulcerative colitis.
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